Top

Published in:

Open Access 01-12-2021 | Breast Cancer | Research article

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Authors: Mark G. Anderson, Qian Zhang, Luis E. Rodriguez, Claudie M. Hecquet, Cherrie K. Donawho, Peter J. Ansell, Edward B. Reilly

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Prolactin receptor (PRLR) is an attractive antibody therapeutic target with expression across a broad population of breast cancers. Antibody efficacy, however, may be limited to subtypes with either PRLR overexpression and/or those where estradiol no longer functions as a mitogen and are, therefore, reliant on PRLR signaling for growth. In contrast a potent PRLR antibody-drug conjugate (ADC) may provide improved therapeutic outcomes extending beyond either PRLR overexpressing or estradiol-insensitive breast cancer populations.

Methods

We derived a novel ADC targeting PRLR, ABBV-176, that delivers a pyrrolobenzodiazepine (PBD) dimer cytotoxin, an emerging class of warheads with enhanced potency and broader anticancer activity than the clinically validated auristatin or maytansine derivatives. This agent was tested in vitro and in vivo cell lines and patient derived xenograft models.

Results

In both in vitro and in vivo assays, ABBV-176 exhibits potent cytotoxicity against multiple cell line and patient-derived xenograft breast tumor models, including triple negative and low PRLR expressing models insensitive to monomethyl auristatin (MMAE) based PRLR ADCs. ABBV-176, which cross links DNA and causes DNA breaks by virtue of its PBD warhead, also demonstrates enhanced anti-tumor activity in several breast cancer models when combined with a poly-ADP ribose polymerase (PARP) inhibitor, a potentiator of DNA damage.

Conclusions

Collectively the efficacy and safety profile of ABBV-176 suggest it may be an effective therapy across a broad range of breast cancers and other cancer types where PRLR is expressed with the potential to combine with other therapeutics including PARP inhibitors.

Available only for authorised users

Breast cancer [https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/].

U.S. Breast Cancer Statistics [https://www.breastcancer.org/symptoms/understand_bc/statistics].

Martei YM, Matro JM. Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes. Breast Cancer (Dove Med Press). 2015;7:337–43. https://doi.org/10.2147/BCTT.S91981.CrossRef

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, et al. Preclinical activity of the novel anti-prolactin receptor (PRLR) antibody-drug conjugate REGN2878-DM1 in PRLR-positive breast cancers. Mol Cancer Ther. 2017;16(7):1299–311. https://doi.org/10.1158/1535-7163.MCT-16-0839.CrossRefPubMed

Andreev J, Thambi N, Perez Bay AE, Delfino F, Martin J, Kelly MP, et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol Cancer Ther. 2017;16(4):681–93. https://doi.org/10.1158/1535-7163.MCT-16-0658.CrossRefPubMed

Zhou Y, Zong H, Han L, Xie Y, Jiang H, Gilly J, et al. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J Exp Clin Cancer Res. 2020;39(1):87. https://doi.org/10.1186/s13046-020-01564-4.CrossRefPubMedPubMedCentral

Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, et al. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene. 2007;26(4):543–53. https://doi.org/10.1038/sj.onc.1209838.CrossRefPubMed

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res. 2011;13(1):R11. https://doi.org/10.1186/bcr2819.CrossRefPubMedPubMedCentral

Damiano JS, Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res. 2013;19(7):1644–50. https://doi.org/10.1158/1078-0432.CCR-12-0138.CrossRefPubMed

10.

Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther. 2013;12(3):295–305. https://doi.org/10.1158/1535-7163.MCT-12-0886.CrossRefPubMed

11.

Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998;83(2):667–74. https://doi.org/10.1210/jcem.83.2.4564.CrossRefPubMed

12.

Faupel-Badger JM, Duggan MA, Sherman ME, Garcia-Closas M, Yang XR, Lissowska J, et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5(1):42–50. https://doi.org/10.1007/s12672-013-0165-7.CrossRefPubMed

13.

Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol. 2007;25(12):1482–8. https://doi.org/10.1200/JCO.2006.07.6356.CrossRefPubMed

14.

Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer. 1984;34(3):323–8. https://doi.org/10.1002/ijc.2910340307.CrossRefPubMed

15.

Bhatavdekar JM, Patel DD, Karelia NH, Shah NG, Ghosh N, Vora HH, et al. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer? Eur J Surg Oncol. 1994;20(2):118–21.PubMed

16.

Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol. 2000;26(6):540–7. https://doi.org/10.1053/ejso.2000.0943.CrossRefPubMed

17.

LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi el M, Afton SE, Ben-Jonathan N: Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 2009, 30(8):1298–1304, DOI: https://doi.org/10.1093/carcin/bgp120.

18.

Agarwal N, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, et al. Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate Cancer. Oncologist. 2016;21(5):535–6. https://doi.org/10.1634/theoncologist.2015-0502.CrossRefPubMedPubMedCentral

19.

Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–84. https://doi.org/10.1038/nbt832.CrossRefPubMed

20.

Kabat AM. Sequences of proteins of immunological interest. 5th ed. Bethesda, MD: U.S. Department of Health and Human Services; 1991.

21.

Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24(7):1256–63. https://doi.org/10.1021/bc400217g.CrossRefPubMed

22.

Anderson MG, Falls HD, Mitten MJ, Oleksijew A, Vaidya KS, Boghaert ER, et al. Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate. Mol Cancer Ther. 2020;19(10):2117–25. https://doi.org/10.1158/1535-7163.MCT-20-0149.CrossRefPubMed

23.

Yonamine K, Hayashi K, Iida T. Establishment and characterization of human ovarian clear cell adenocarcinoma cell line (SMOV-2), and its cytotoxity by anticancer agents. Hum Cell. 1999;12(3):139–48.PubMed

24.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, et al. Anti-c-met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016;16(1):105. https://doi.org/10.1186/s12885-016-2138-z.CrossRefPubMedPubMedCentral

25.

Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, et al. ABBV-399, a c-met antibody-drug conjugate that targets both MET-amplified and c-met-overexpressing tumors, irrespective of MET pathway dependence. Clin Cancer Res. 2017;23(4):992–1000. https://doi.org/10.1158/1078-0432.CCR-16-1568.CrossRefPubMed

26.

Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, et al. The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal. 2018;11(557).

27.

Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem. 2003;278(29):27287–92. https://doi.org/10.1074/jbc.M304307200.CrossRefPubMed

28.

Otte JM, Otte C, Beckedorf S, Schmitz F, Vonderhaar BK, Folsch UR, et al. Expression of functional prolactin and its receptor in human colorectal cancer. Int J Color Dis. 2003;18(1):86–94. https://doi.org/10.1007/s00384-002-0414-7.CrossRef

29.

Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, et al. Prostate development and carcinogenesis in prolactin receptor knockout mice. Endocrinology. 2003;144(7):3196–205. https://doi.org/10.1210/en.2003-0068.CrossRefPubMed

30.

Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol. 2011;8(11):597–607. https://doi.org/10.1038/nrurol.2011.143.CrossRefPubMedPubMedCentral

31.

Yeh Y-T, Lee K-T, Tsai C-J, Chen Y-J, Wang S-N. Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg. 2012;36(5):1128–35. https://doi.org/10.1007/s00268-012-1505-4.CrossRefPubMed

32.

Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008;111(2):241–50. https://doi.org/10.1007/s10549-007-9789-z.CrossRefPubMed

33.

Lemech C, Woodward N, Chan N, Mortimer J, Naumovski L, Nuthalapati S, et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Investig New Drugs. 2020;38(6):1815–25. https://doi.org/10.1007/s10637-020-00960-z.CrossRef

34.

Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24(1):15–28. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2013006875.CrossRefPubMedPubMedCentral

35.

Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18(3):168–85. https://doi.org/10.1038/nrc.2017.116.CrossRefPubMed

36.

Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, et al. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer. 2010;9(1):127. https://doi.org/10.1186/1476-4598-9-127.CrossRefPubMedPubMedCentral

37.

Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, et al. Improved therapeutic window in BRCA-mutant tumors with antibody-linked Pyrrolobenzodiazepine dimers with and without PARP inhibition. Mol Cancer Ther. 2019;18(1):89–99. https://doi.org/10.1158/1535-7163.MCT-18-0314.CrossRefPubMed

Title: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
Authors: Mark G. Anderson
Qian Zhang
Luis E. Rodriguez
Claudie M. Hecquet
Cherrie K. Donawho
Peter J. Ansell
Edward B. Reilly
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08403-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010

Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study

Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Keynote webinar | Spotlight on antibody–drug conjugates in cancer